Home

Corona Remedies Ltd EPS

Image

Corona Remedies Ltd

NSE: CORONA

EPS

₹ 24.52

Last updated on: Jan 13, 2026

Key Highlights

  • The Earning per Share of Corona Remedies Ltd is ₹ 24.52 as of 13 Jan 26 .
  • The earning per share of Corona Remedies Ltd changed from ₹ 4.9 to ₹ 8.55 over 4 quarters. This represents a CAGR of 74.49% .

Historical Earning per Share of Corona Remedies Ltd

No data available

* All values are in

Company Fundamentals for null

Market Cap

8,791 Cr

EPS

24.5

P/E Ratio (TTM)

57.2

P/B Ratio (TTM)

14.1

Day’s High

1465.0

Day’s Low

1398.5

DTE

0.1

ROE

41.5

52 Week High

1523.95

52 Week Low

1336.95

ROCE

51.9

Market Price of Corona Remedies Ltd

1M

1Y

3Y

5Y

Monitoring Corona Remedies Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
13 Jan 20261437.45
12 Jan 20261402.7
09 Jan 20261425.6
08 Jan 20261463.85
07 Jan 20261446.9
06 Jan 20261430.35
05 Jan 20261466.5
02 Jan 20261445.7
01 Jan 20261402.95
31 Dec 20251385.85

SWOT Analysis Of Corona Remedies Ltd

Strength

1

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Corona Remedies Ltd

Asset Value vs Market Value of Corona Remedies Ltd

Market Value

8,579

Asset Value

Value addition

22.7 X

362

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Corona Remedies Ltd8578
Sun Pharmaceutical Industries Ltd415037
Divis Laboratories Ltd170795
Torrent Pharmaceuticals Ltd133332
Cipla Ltd116933
Lupin Ltd99436

Historical Market Cap of Corona Remedies Ltd

No data available

* All values are in crore

Historical Revenue of Corona Remedies Ltd

No data available

* All values are in crore

Historical EBITDA of Corona Remedies Ltd

No data available

* All values are in crore

Historical Net Profit of Corona Remedies Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Corona Remedies Ltd News Hub

Shares of Corona Remedies list in B group

The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and

Read more

15 Dec 25

Corona Remedies Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

03 Jan 26

Corona Remedies gains as Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

05 Jan 26

Corona Remedies spurts on market debut

The stock was listed at Rs 1,452, exhibiting a premium of 36.72% to the issue price. So far, the sto

Read more

15 Dec 25

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of null

What is the EPS of Corona Remedies Ltd stock?

The Earnings Per Share (EPS) of Corona Remedies Ltd is 24.52. An EPS is the amount of net income attributed to each share of a common stock.

How is Corona Remedies Ltd EPS calculated?

The EPS of Corona Remedies Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Corona Remedies Ltd report its EPS?

Corona Remedies Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Corona Remedies Ltd EPS?

Factors that influence the EPS of Corona Remedies Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Corona Remedies Ltd EPS growth indicate future performance?

Yes, consistent growth in Corona Remedies Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions